Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.

Protein Kinase C (PKC) plays a major role in the regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. PKC exists as a family of closely related subspecies, has a heterogeneous distribution in the brain (with particularly high levels in presynaptic nerve terminals), and plays a crucial role in the regulation of neuronal excitability, neurotransmitter release, regulation of synaptic plasticity and various forms of learning and memory. Research findings show that the PKC pathway can be used as a target for developing treatment strategies for bipolar disorder. Endoxifen exhibited activity in inhibiting the PKC activity.

In patients with acute bipolar mania, rapid reduction of symptoms is a key treatment goal; however, there is also a need for effective maintenance of effect treatment beyond the period of acute stabilization. The current study will evaluate the efficacy and safety of Endoxifen in Bipolar I Disorder patients against a control placebo arm.

Inclusion Criteria:

1. Male ≥18 to ≤65 years of age and postmenopausal female patients (12 months with no menses without an alternative medical cause) willing to give written informed consent along with at least one first degree relative (the legally acceptable representative [LAR]) to participate in the study before initiating any study related procedures.
2. Six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL; OR have had surgical bilateral oophorectomy (with or without hysterectomy) at least six months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment if she is considered not of child-bearing potential.
3. Patients must have a diagnosis of bipolar I disorder and currently display an acute manic episode with or without mixed features according to DSM-5 criteria as judged by the Investigator.
4. Young Mania Rating Scale (YMRS) total score of > 25 and ≥4 on two of four core items (irritability, speech, content, disruptive/aggressive behavior) at screening and at randomization (baseline). The optimal YMRS23 severity threshold of 25 was chosen as this corresponds to a Positive Predictive Value (PPV) of 83%, signifying that 83% of patients with a baseline score ≥ 25 are at least "Markedly ill".
5. Score of >4 in Severity of illness criteria of Clinical Global Impressions- bipolar disorder (CGI-BP) Scale for overall illness at screening and at randomization (baseline).
6. Ready for voluntary hospitalization (along with the accompanying LAR if required and as advised by the Investigator) for the current manic episode for a minimum of 2 days prior to randomization through 21 days of in-patient treatment period.
7. Last intake of the medication(s) for BPD should be 2-7 days prior to randomization depending upon the individual drug's plasma half-life.
8. Patient and / or LAR understand and agree to comply with all the study requirements.
9. Male patients of child begetting potential must be practicing adequate contraception, and any female partners must agree to the use of, highly effective contraception. Documentation should be provided for surgical sterilization for male patients not of child begetting potential.

11. Patient has not taken and agrees not to take any medication or therapy prohibited by the protocol (refer to listing in Section 14.7) for the entire study period.

12. Patients not having any significant diseases or clinically significant abnormal findings except BPD during screening-including medical history, physical examination, laboratory evaluations, 12-lead ECG and X-ray chest (postero- anterior view) recording, etc. which is likely to adversely affect patient's safety and may impact the clinical outcome of the study by participating in the study or study objectives in Investigator's opinion.

13. Subjects judged clinically not to be at serious suicide risk, (all responses to the Baseline C-SSRS as "No"), or homicidal risk per clinical questioning.

Exclusion Criteria:

1. Newly diagnosed patients not having any suitable treatment exposure in the past for their bipolar mood disorder.

2. ≥ 20% improvement in YMRS total scores between screening and randomization visits.

3. Patients who meet DSM-5criteria for any psychiatric disorder other than Bipolar I Disorder with Acute manic episodes with or without mixed features

4. Patients with seizure disorder

5. Obsessive compulsive disorder or any other co-morbid Axis I anxiety disorder

6. Patients with borderline or anti-social personality disorder of sufficient current severity to interfere with conduct of the study

7. Patients with classical premenopausal symptoms were found at risk of developing intolerable hot flushes, irregular vaginal bleeding.

8. Use of the following medications:

   • Antihypertensive agents if stable dose has not been administered for at least 1 month before randomization
   • Antidepressants in the week (or a period of 5 half-lives of the drug) prior to randomization
   • Continuous daily or standing orders use of benzodiazepines during the month preceding screening (approximately 5 weeks prior to screening)
   • Potent cytochrome P450 (CYP) inducers and CYP2D6/CYP3A4 inhibitors 14 days prior to randomization
   • Depot antipsychotic medications within 1 dosing interval prior to randomization
   • Use of systemic estrogens 6 weeks prior to randomization
   • Patients currently on carbapenem agents

9. Any of the following laboratory abnormalities

   • Serum bilirubin ≥ 1.5 times ULN
   • Serum AST/ALT ≥ 2.5 times ULN
   • Serum TSH >10% above the ULN, regardless of treatment for hypothyroidism or hyperthyroidism
   • Serum triglyceride level > 2.5 times ULN

10. Patients with the following cardiac conditions are excluded:

    • Recent myocardial infarction (<12 months)
    • QTc prolongation (screening electrocardiogram with QTc > 450 msec for men, QTc > 470 msec for women)
    • History of QTc prolongation or using concomitant medications (as judged by the Investigator) which prolong QTc interval
    • Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia
    • Decompensatory congestive heart failure
    • Complete left bundle branch block
    • First-degree heart block with PR interval > 0.22 seconds

11. Presence of a coagulation disorder; active or past history of venous thromboembolism including deep venous thrombosis or pulmonary embolism

12. Current prolonged immobilization

13. History or current presence of retinal pathology including retinal vein thrombosis

14. Increased risk of stroke as per the Investigator's discretion

15. History of hypersensitivity or intolerance to tamoxifen, or any other ingredients of the preparation

16. Serious, unstable illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease as per history and medical examination.

17. Drug screen positive for any drug of abuse at screening, (except for benzodiazepines used in therapeutic dose for management of acute mania), active substance abuse in the past 2 months or history of substance dependence (excluding nicotine and caffeine) within 3 months of screening.

18. History of breast or uterine cancer, or abnormal uterine bleeding.

19. Current leukopenia or thrombocytopenia as judged by the Investigator in the best health interest of the subject.

20. Clinically significant suicidal (subject responds "Yes" to any category for Baseline C-SSRS) or homicidal ideation per clinical questioning.

21. Participation in a clinical trial of another investigational drug within 30 days prior to screening.

All subjects, investigators and research staff will be blinded to the treatment allocation. Only personnel who are not involved in the interpretation and analysis of the study data will be allowed access to the blinded information